Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Single and Multi-dose, Placebo Controlled, Randomized, Dose-Escalation Study to Evaluate the Safety, Tolerability and PK Profile of MP-376 Using the PARI eFlow Nebulizer for 14 Days to CF Patients

NCT00503490 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00503490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00503490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Single and Multi-dose, Placebo Controlled, Randomized, Dose-Escalation Study to Evaluate the Safety, Tolerability and PK Profile of MP-376 Using the PARI eFlow Nebulizer for 14 Days to CF Patients
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2007
Completion date
December 31, 2007
Enrollment
40 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis